Legend Biotech Corporation has announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in the treatment of relapsed/refractory multiple myeloma. Results from the CARTITUDE-1 and CARTITUDE-4 studies indicate that triple-class exposed patients with three prior lines of therapy achieved a median progression-free survival of 50.4 months after a single infusion of CARVYKTI®. Additional data show that 80% of as-treated patients in CARTITUDE-4 with standard-risk cytogenetics remained progression-free and off treatment at 30 months. The company also reported promising first-in-human results from its allogeneic CAR-T candidate LUCAR-G39D in B-cell non-Hodgkin lymphoma. These findings were presented at the American Society of Hematology $(ASH)$ 2025 annual meeting.